Subscribe to Newsletter

Business Practice

Discovery & Development Business Practice

NanoSight Nanoparticle Tracking Analysis Concentration Measurement

The ability to compare concentration data across users, instruments and sites is a key requirement for many applications. Concentration repeatability and reproducibility are greatly improved with the application of the NTA concentration measurement upgrade, which has also been shown to reduce the influence of user selected capture and analysis settings on measurements. This application note describes the improvement in accuracy and precision of concentration measurements over a wide range of sample sizes, concentrations and materials.

Discovery & Development Business Practice

Relative viscosity screening of monoclonal antibody formulations at low concentration and viscosity

Viscosizer TD provides automated relative viscosity measurements with high reproducibility at low viscosity, to help identify molecules with abnormally high viscosity-concentration profiles at low sample concentrations as early as possible in the development pipeline

Business & Regulation Business Practice

Helping or Hindering Science?

| Michael Merrifield, Chris Leigh

Astronomers Chris Leigh and Mike Merrifield debate how a potential Brexit might impact UK science

Business & Regulation Business Practice

Why the BIA Says No to a Brexit

| Steve Bates

Steve Bates, CEO of the British BioIndustry Association (BIA) explains why he thinks the UK bioindustry is stronger inside the European Union.

Discovery & Development Business Practice

Trials and Tribulations

| Angus Dalgleish

Angus Dalgleish tells us about his experience with EU regulation – and why he thinks Britain should leave the EU.

Business & Regulation Business Practice

The Great British Debate

| James Strachan

As politicians and the public argue over the minor point of the UK leaving Europe, we ask a more important question: what will a “Brexit” mean for the global pharmaceutical industry?

Business & Regulation Business Practice

Open Door IP

| Charlotte Berg-Svendsen

Intellectual property issues have suffocated many industry collaborations. And though IP is clearly valuable to pharma companies, there is also value in learning to let go.

Business & Regulation Business Practice

CSRxP Vs PhRMA

| James Strachan

A US coalition seeks lower prices for US prescription drugs, but could their proposals undermine the competitive market?

Business & Regulation Business Practice

Pharma on a Merger Mission

| James Strachan

Abbott, Abbvie and Sanofi all make separate merger announcements – on the same day

Business & Regulation Business Practice

Getting the Message Across

| James Strachan

What’s the best way to present a health resource? Apparently, ease of use trumps all other factors

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register